Disc Medicine, Inc. Research and Development Expense
Disc Medicine, Inc. (IRON) reported Research and Development Expense of $46.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-30
- Disc Medicine, Inc. research and development expense for the quarter ending 2026-06-30 was $46.93M, a 1.33% increase year-over-year.
- Disc Medicine, Inc. research and development expense for the quarter ending 2026-03-31 was $45.90M, a 65.34% increase year-over-year.
- Disc Medicine, Inc. research and development expense for the quarter ending 2025-12-31 was $46.22M, a 86.41% increase year-over-year.
- Disc Medicine, Inc. research and development expense for the quarter ending 2025-09-30 was $50.33M, a 103.91% increase year-over-year.
- Disc Medicine, Inc. research and development expense for fiscal 2025 was $170.64M, a 76.52% increase from fiscal 2024.
- Disc Medicine, Inc. research and development expense for fiscal 2024 was $96.67M, a 39.57% increase from fiscal 2023.
- Disc Medicine, Inc. research and development expense for fiscal 2023 was $69.26M, a 107.15% increase from fiscal 2022.
- Disc Medicine, Inc. research and development expense for fiscal 2022 was $33.44M, a 32.84% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $46.93M 10-Q · filed 2026-07-30 | $92.84M 10-Q · filed 2026-07-30 | $139.06M derived: sum of 3 quarters · filed 2026-07-30 | $189.40M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $45.90M 10-Q · filed 2026-05-05 | $92.13M derived: sum of 2 quarters · filed 2026-05-05 | $142.46M derived: sum of 3 quarters · filed 2026-05-05 | $188.78M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $46.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $96.56M derived: sum of 2 quarters · filed 2026-02-26 | $142.88M derived: sum of 3 quarters · filed 2026-07-30 | $170.64M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $50.33M 10-Q · filed 2025-11-06 | $96.65M derived: sum of 2 quarters · filed 2026-07-30 | $124.42M 10-Q · filed 2025-11-06 | $149.21M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $46.32M 10-Q · filed 2026-07-30 | $74.08M 10-Q · filed 2026-07-30 | $98.88M derived: sum of 3 quarters · filed 2026-07-30 | $123.56M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $27.76M 10-Q · filed 2026-05-05 | $52.56M derived: sum of 2 quarters · filed 2026-05-05 | $77.25M derived: sum of 3 quarters · filed 2026-05-05 | $100.73M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $24.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $49.48M derived: sum of 2 quarters · filed 2026-02-26 | $72.97M derived: sum of 3 quarters · filed 2026-02-26 | $96.67M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $24.68M 10-Q · filed 2025-11-06 | $48.17M derived: sum of 2 quarters · filed 2025-11-06 | $71.87M 10-Q · filed 2025-11-06 | $94.44M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $23.48M 10-Q · filed 2025-08-07 | $47.19M 10-Q · filed 2025-08-07 | $69.75M derived: sum of 3 quarters · filed 2026-02-26 | $84.17M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $23.70M 10-Q · filed 2025-05-07 | $46.27M derived: sum of 2 quarters · filed 2026-02-26 | $60.69M derived: sum of 3 quarters · filed 2026-02-26 | $72.79M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $22.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $36.98M derived: sum of 2 quarters · filed 2026-02-26 | $49.08M derived: sum of 3 quarters · filed 2026-02-26 | $69.26M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $14.42M 10-Q · filed 2024-11-12 | $26.52M derived: sum of 2 quarters · filed 2024-11-12 | $46.70M 10-Q · filed 2024-11-12 | $56.72M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $12.10M 10-Q · filed 2024-08-08 | $32.28M 10-Q · filed 2024-08-08 | $42.30M derived: sum of 3 quarters · filed 2024-08-08 | $50.18M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $20.18M 10-Q · filed 2024-05-09 | $30.20M derived: sum of 2 quarters · filed 2024-05-09 | $38.08M derived: sum of 3 quarters · filed 2024-05-09 | $45.80M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $10.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $17.90M derived: sum of 2 quarters · filed 2024-03-21 | $25.62M derived: sum of 3 quarters · filed 2024-03-21 | $33.44M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | $7.89M 10-Q · filed 2023-11-09 | $438.00K 10-Q · filed 2022-11-10 | $15.60M derived: sum of 2 quarters · filed 2023-11-09 | $23.42M 10-Q · filed 2023-11-09 | $12.82M 10-Q · filed 2022-11-10 | $12.51M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $7.71M 10-Q · filed 2023-08-11 | $2.58M 10-Q · filed 2022-08-11 | $15.54M 10-Q · filed 2023-08-11 | $12.38M 10-Q · filed 2022-08-11 | $4.62M derived: sum of 3 quarters · filed 2023-08-11 | $18.08M derived: sum of 4 quarters · filed 2023-08-11 | ||
| 2022-03-31 | $7.82M 10-Q · filed 2023-05-15 | $9.80M 10-Q · filed 2022-05-06 | -$3.09M derived: sum of 2 quarters · filed 2023-05-15 | $10.36M derived: sum of 3 quarters · filed 2023-05-15 | $21.20M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$10.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $2.54M derived: sum of 2 quarters · filed 2023-03-31 | $13.38M derived: sum of 3 quarters · filed 2023-03-31 | $25.17M 10-K · filed 2023-03-31 | $48.72M 10-K · filed 2022-03-10 | |||
| 2021-09-30 | $13.46M 10-Q · filed 2022-11-10 | $24.30M derived: sum of 2 quarters · filed 2022-11-10 | $36.08M 10-Q · filed 2022-11-10 | $43.78M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $10.84M 10-Q · filed 2022-08-11 | $22.63M 10-Q · filed 2022-08-11 | $30.33M derived: sum of 3 quarters · filed 2022-08-11 | $37.05M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $11.79M 10-Q · filed 2022-05-06 | $19.48M derived: sum of 2 quarters · filed 2022-05-06 | $26.21M derived: sum of 3 quarters · filed 2022-05-06 | $31.74M derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | $7.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $14.43M derived: sum of 2 quarters · filed 2022-03-10 | $19.95M derived: sum of 3 quarters · filed 2022-03-10 | $28.17M 10-K · filed 2022-03-10 | ||||
| 2020-09-30 | $6.73M 10-Q · filed 2021-11-15 | $12.26M derived: sum of 2 quarters · filed 2021-11-15 | $20.47M 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $5.53M 10-Q · filed 2021-08-12 | $13.74M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $8.22M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |